IDH2 and astrocytoma (excluding glioblastoma): Methylation profiling of the glial component of the recurrence matched with high confidence to methylation class astrocytoma, IDH-mutant, low-grade (0.99); however, the sarcoma matched with high confidence to the MC oligosarcoma, IDH-mutant, with a final confidence score of 0.90.